questionsmedicales.fr
Composés polycycliques
Hydrocarbures aromatiques polycycliques
Benzocycloheptènes
Benzocycloheptènes : Questions médicales fréquentes
Termes MeSH sélectionnés :
Combined Modality Therapy
Diagnostic
5
Spectroscopie
Chromatographie
Tests de toxicité
Efficacité
Analyse sanguine
Échantillons biologiques
Marqueurs biologiques
Exposition
Imagerie moléculaire
Distribution tissulaire
Symptômes
5
Effets secondaires
Réactions allergiques
Symptômes neurologiques
Troubles de la coordination
Éruptions cutanées
Réaction allergique
Système respiratoire
Irritations
Prévention
5
Équipements de protection
Protocoles de sécurité
Milieu industriel
Exposition
Réglementations
Usage industriel
Évaluation des risques
Environnements de travail
Traitements
5
Intoxication
Soins symptomatiques
Antidotes
Composés chimiques
Antihistaminiques
Réactions allergiques
Hospitalisation
Symptômes graves
Suivi médical
Effets à long terme
Complications
5
Complications
Lésions organiques
Cancers
Potentiel cancérigène
Effets sur la reproduction
Études animales
Allergies
Sensibilisations
Système immunitaire
Infections
Facteurs de risque
5
Travailleurs
Industrie chimique
Prédispositions génétiques
Sensibilité aux toxines
Antécédents médicaux
Allergies
Environnement de travail
Ventilation
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Benzocycloheptènes : Questions médicales les plus fréquentes",
"headline": "Benzocycloheptènes : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Benzocycloheptènes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-11",
"dateModified": "2025-03-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Benzocycloheptènes"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Hydrocarbures aromatiques polycycliques",
"url": "https://questionsmedicales.fr/mesh/D011084",
"about": {
"@type": "MedicalCondition",
"name": "Hydrocarbures aromatiques polycycliques",
"code": {
"@type": "MedicalCode",
"code": "D011084",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Dibenzocycloheptènes",
"alternateName": "Dibenzocycloheptenes",
"url": "https://questionsmedicales.fr/mesh/D003986",
"about": {
"@type": "MedicalCondition",
"name": "Dibenzocycloheptènes",
"code": {
"@type": "MedicalCode",
"code": "D003986",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Amitriptyline",
"alternateName": "Amitriptyline",
"url": "https://questionsmedicales.fr/mesh/D000639",
"about": {
"@type": "MedicalCondition",
"name": "Amitriptyline",
"code": {
"@type": "MedicalCode",
"code": "D000639",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Butaclamol",
"alternateName": "Butaclamol",
"url": "https://questionsmedicales.fr/mesh/D002069",
"about": {
"@type": "MedicalCondition",
"name": "Butaclamol",
"code": {
"@type": "MedicalCode",
"code": "D002069",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.230"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cyproheptadine",
"alternateName": "Cyproheptadine",
"url": "https://questionsmedicales.fr/mesh/D003533",
"about": {
"@type": "MedicalCondition",
"name": "Cyproheptadine",
"code": {
"@type": "MedicalCode",
"code": "D003533",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.340"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Loratadine",
"alternateName": "Loratadine",
"url": "https://questionsmedicales.fr/mesh/D017336",
"about": {
"@type": "MedicalCondition",
"name": "Loratadine",
"code": {
"@type": "MedicalCode",
"code": "D017336",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.340.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Loratadine",
"alternateName": "Loratadine",
"url": "https://questionsmedicales.fr/mesh/D017336",
"about": {
"@type": "MedicalCondition",
"name": "Loratadine",
"code": {
"@type": "MedicalCode",
"code": "D017336",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.340.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Maléate de dizocilpine",
"alternateName": "Dizocilpine Maleate",
"url": "https://questionsmedicales.fr/mesh/D016291",
"about": {
"@type": "MedicalCondition",
"name": "Maléate de dizocilpine",
"code": {
"@type": "MedicalCode",
"code": "D016291",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.380"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nortriptyline",
"alternateName": "Nortriptyline",
"url": "https://questionsmedicales.fr/mesh/D009661",
"about": {
"@type": "MedicalCondition",
"name": "Nortriptyline",
"code": {
"@type": "MedicalCode",
"code": "D009661",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.535"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protriptyline",
"alternateName": "Protriptyline",
"url": "https://questionsmedicales.fr/mesh/D011530",
"about": {
"@type": "MedicalCondition",
"name": "Protriptyline",
"code": {
"@type": "MedicalCode",
"code": "D011530",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.650"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Benzocycloheptènes",
"alternateName": "Benzocycloheptenes",
"code": {
"@type": "MedicalCode",
"code": "D001567",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jiatian Li",
"url": "https://questionsmedicales.fr/author/Jiatian%20Li",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
},
{
"@type": "Person",
"name": "Xiangwen Tan",
"url": "https://questionsmedicales.fr/author/Xiangwen%20Tan",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
},
{
"@type": "Person",
"name": "Huanfeng Jiang",
"url": "https://questionsmedicales.fr/author/Huanfeng%20Jiang",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
},
{
"@type": "Person",
"name": "Wanqing Wu",
"url": "https://questionsmedicales.fr/author/Wanqing%20Wu",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Survivorship in Early-Stage Rectal Cancer Patients Who Have Received Combined Modality Therapy.",
"datePublished": "2023-08-06",
"url": "https://questionsmedicales.fr/article/37586927",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clcc.2023.08.002"
}
},
{
"@type": "ScholarlyArticle",
"name": "Combined modality therapy for patients with esophageal squamous cell carcinoma: Radiation dose and survival analyses.",
"datePublished": "2022-11-09",
"url": "https://questionsmedicales.fr/article/36351568",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/1759-7714.14724"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cost-Effectiveness of PET Directed Versus Combined Modality Therapy for Early-Stage Favorable Hodgkin's Lymphoma.",
"datePublished": "2022-07-17",
"url": "https://questionsmedicales.fr/article/35963771",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clml.2022.07.005"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessment of Patient-Reported Outcomes in Patients With Anal Squamous-Cell Cancer Undergoing Combined Modality Therapy.",
"datePublished": "2022-09-05",
"url": "https://questionsmedicales.fr/article/36102865",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/DCR.0000000000002600"
}
},
{
"@type": "ScholarlyArticle",
"name": "PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK).",
"datePublished": "2022-09-10",
"url": "https://questionsmedicales.fr/article/36099671",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejca.2022.07.027"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011083"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hydrocarbures aromatiques polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011084"
},
{
"@type": "ListItem",
"position": 4,
"name": "Benzocycloheptènes",
"item": "https://questionsmedicales.fr/mesh/D001567"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Benzocycloheptènes - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Benzocycloheptènes",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Benzocycloheptènes",
"description": "Comment identifier les benzocycloheptènes ?\nQuels tests sont utilisés pour les benzocycloheptènes ?\nLes benzocycloheptènes sont-ils détectables dans le sang ?\nY a-t-il des marqueurs spécifiques pour ces composés ?\nPeut-on utiliser l'imagerie pour les benzocycloheptènes ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Combined+Modality+Therapy#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Benzocycloheptènes",
"description": "Quels sont les effets secondaires des benzocycloheptènes ?\nLes benzocycloheptènes causent-ils des douleurs ?\nY a-t-il des symptômes neurologiques associés ?\nPeut-on observer des symptômes cutanés ?\nLes benzocycloheptènes affectent-ils le système respiratoire ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Combined+Modality+Therapy#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Benzocycloheptènes",
"description": "Comment prévenir l'exposition aux benzocycloheptènes ?\nY a-t-il des formations pour manipuler ces composés ?\nQuels sont les risques en milieu industriel ?\nDes réglementations existent-elles pour leur usage ?\nComment évaluer les risques d'exposition ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Combined+Modality+Therapy#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Benzocycloheptènes",
"description": "Comment traiter une intoxication aux benzocycloheptènes ?\nY a-t-il des antidotes pour ces composés ?\nQuels médicaments peuvent aider en cas d'allergie ?\nLes benzocycloheptènes nécessitent-ils une hospitalisation ?\nComment gérer les effets à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Combined+Modality+Therapy#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Benzocycloheptènes",
"description": "Quelles complications peuvent survenir avec ces composés ?\nLes benzocycloheptènes peuvent-ils causer des cancers ?\nY a-t-il des effets sur la reproduction ?\nPeut-on développer des allergies à long terme ?\nLes benzocycloheptènes affectent-ils le système immunitaire ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Combined+Modality+Therapy#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Benzocycloheptènes",
"description": "Qui est le plus à risque d'exposition ?\nL'âge influence-t-il la sensibilité ?\nY a-t-il des prédispositions génétiques ?\nLes antécédents médicaux jouent-ils un rôle ?\nL'environnement de travail influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Combined+Modality+Therapy#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les benzocycloheptènes ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par des techniques de spectroscopie et de chromatographie."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les benzocycloheptènes ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de toxicité et d'efficacité sont réalisés en laboratoire."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes sont-ils détectables dans le sang ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être détectés par des analyses spécifiques dans des échantillons biologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour ces composés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs biologiques peuvent indiquer l'exposition à ces composés."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour les benzocycloheptènes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie moléculaire peut aider à visualiser leur distribution dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des benzocycloheptènes ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent provoquer des nausées, des vertiges ou des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes causent-ils des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs peuvent survenir en cas de toxicité ou d'allergie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des maux de tête ou des troubles de la coordination peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cutanés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées peuvent survenir en cas de réaction allergique."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes affectent-ils le système respiratoire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition excessive peut entraîner des irritations respiratoires."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'exposition aux benzocycloheptènes ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des équipements de protection et suivre les protocoles de sécurité en laboratoire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des formations pour manipuler ces composés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des formations spécifiques sont souvent requises pour les chercheurs."
}
},
{
"@type": "Question",
"name": "Quels sont les risques en milieu industriel ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs peuvent être exposés à des niveaux élevés sans protection adéquate."
}
},
{
"@type": "Question",
"name": "Des réglementations existent-elles pour leur usage ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des réglementations strictes encadrent leur utilisation en laboratoire et en industrie."
}
},
{
"@type": "Question",
"name": "Comment évaluer les risques d'exposition ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des évaluations de risque doivent être effectuées régulièrement dans les environnements de travail."
}
},
{
"@type": "Question",
"name": "Comment traiter une intoxication aux benzocycloheptènes ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'élimination de l'exposition et des soins symptomatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des antidotes pour ces composés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas d'antidote spécifique pour les benzocycloheptènes."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent aider en cas d'allergie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antihistaminiques peuvent être utilisés pour traiter les réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes nécessitent-ils une hospitalisation ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une hospitalisation peut être nécessaire en cas de symptômes graves."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier est recommandé pour surveiller les effets à long terme."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces composés ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des lésions organiques peuvent survenir en cas d'exposition prolongée."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes peuvent-ils causer des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un potentiel cancérigène, mais des recherches supplémentaires sont nécessaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets sur la reproduction ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets néfastes sur la reproduction ont été observés dans certaines études animales."
}
},
{
"@type": "Question",
"name": "Peut-on développer des allergies à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des sensibilisations peuvent se développer avec une exposition répétée."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes affectent-ils le système immunitaire ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition prolongée peut altérer la fonction immunitaire, augmentant les infections."
}
},
{
"@type": "Question",
"name": "Qui est le plus à risque d'exposition ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs en laboratoire et en industrie chimique sont les plus exposés."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il la sensibilité ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes et les personnes âgées peuvent être plus sensibles aux effets toxiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines prédispositions génétiques peuvent augmenter la sensibilité aux toxines."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents d'allergies ou de maladies respiratoires augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'environnement de travail influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un environnement de travail mal ventilé augmente le risque d'exposition."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
1 publication dans cette catégorie
Affiliations :
Publications dans "Benzocycloheptènes" :
1 publication dans cette catégorie
Affiliations :
Publications dans "Benzocycloheptènes" :
1 publication dans cette catégorie
Affiliations :
Publications dans "Benzocycloheptènes" :
1 publication dans cette catégorie
Affiliations :
Publications dans "Benzocycloheptènes" :
Survival rates in early-stage rectal cancer patients have increased over the past few decades. Societies such as the National Comprehensive Cancer Network (NCCN), American Cancer Society (ACS), Americ...
We aimed to analyze the radiation dose and compare survival among combined modality therapy using modern radiation techniques for patients with esophageal squamous cell carcinoma (ESCC)....
This retrospective study included patients with clinically staged T1-4N0-3M0 ESCC from 2014 to 2018. Patients who received combined modality therapies with curative intent were enrolled. The overall s...
Of the 259 patients, 141 (54.4%) received definitive concurrent chemoradiotherapy (DCCRT); 67 (25.9%) underwent neoadjuvant chemoradiotherapy followed by surgery (NCRT+S); 51 (19.7%) obtained surgery ...
Our results suggest that NCRT+S can provide a favorable survival for patients with ESCC, especially in patients who achieved pCR. The optimal radiation dose might be 55-60 Gy for patients receiving DC...
The standard of care for early-stage Hodgkin Lymphoma (HL) is combined modality therapy (CMT) consisting of chemotherapy and involved site radiation therapy (ISRT). Recent treatment de-escalation tria...
This study used a cost-effectiveness Markov model simulating 5 year outcomes for 1 million patients with early-stage HL treated with either PET-directed therapy consisting of 2 cycles of ABVD chemothe...
We found that PET-directed therapy and CMT strategies were associated with costs of $47,362 and $41,167, respectively. The CMT strategy was equally as effective as the PET-directed therapy strategy wi...
For patients with early-stage HL, CMT is the cost-effective strategy as compared with PET-directed therapy....
There is limited knowledge on long-term bowel, sexual, and urinary function after combined modality therapy for anal squamous-cell cancer....
This study aimed to evaluate long-term changes in patients treated with combined modality....
This was a retrospective study of prospectively collected patient-reported outcome surveys....
This study was conducted at a single institution....
There were 143 patients with stage I to III anal cancer who were treated with chemoradiation and had completed the survey....
This study included patient-reported outcomes reflecting bowel, sexual, and urinary function....
Thirty-nine percent of patients had major low anterior resection syndrome at baseline. Major low anterior resection syndrome remained stable (38%; 95% CI, 31%-46%) with no change over time (OR 0.95; 9...
This was a single-institution study and only patients who answered the questionnaire were included in the study....
A significant proportion of patients have major low anterior resection syndrome at baseline and after successful treatment for anal cancer. Having major low anterior resection syndrome at baseline was...
ANTECEDENTES:Existe un conocimiento limitado sobre la función intestinal, sexual y urinaria a largo plazo después de la terapia de modalidad combinada para el cáncer anal de células escamosas.OBJETIVO...
Positron emission tomography (PET) may differentiate responding and non-responding tumours early in the treatment of locally advanced gastroesophageal junction adenocarcinomas. Early PET non-responder...
Patients underwent baseline...
In total, 160 patients with resectable gastroesophageal junction adenocarcinomas were prospectively investigated by PET scanning. Eighty-five patients (53%) were excluded. Seventy-five eligible patien...
The primary endpoint of the study to increase the R0 resection rate in metabolic NR was not met. PET response after induction CTX is prognostic for outcome with a prolonged OS and DFS in PET responder...
NCT00002014-000860-16....
Facial aging involves multilevel changes, extending from the skin to deep support structures. A comprehensive treatment approach targeting the many aspects of facial dynamics and architecture is often...
To explore the integration of botulinum toxin type A (BoNT-A) into multimodal aesthetic treatment plans....
This article reviews evidence supporting the combination of BoNT-A with other minimally invasive cosmetic therapies, including dermal fillers, lasers, and energy-based devices as well as with plastic ...
Combination treatment protocols including BoNT-A demonstrate higher patient satisfaction and retention rates compared to monotherapy or sequential treatments. Some guidelines for sequencing of treatme...
Integrating BoNT-A into a larger aesthetic treatment plan is crucial for achieving natural and satisfying results in facial rejuvenation. Evidence supports better outcomes when incorporating with both...
Gastrointestinal cancers represent a major challenge to public health. Pancreatic cancer is the most lethal cancer among all gastrointestinal cancers. Most patients cannot meet the criteria of resecti...
Neoadjuvant chemotherapy helps some patients regain the opportunity of radical resection. An optimal regimen of chemotherapy is one that maximizes the anti-tumor efficacy while maintaining a relativel...
Combination therapies in a multidisciplinary manner that involves modified chemotherapy regimen, radical resection, and intestine auto-transplantation may provide the currently best possible care to p...
Loop diuretics are the cornerstone of the treatment of volume overload in decompensated heart failure. However, often complete decongestion cannot be achieved rapidly with loop diuretics alone, partly...
Immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy have limited efficacy in treating advanced hepatocellular carcinoma (HCC). The synergistic effect of systemic therapy and radia...
This retrospective observational study analyzed the medical records of 194 patients with Barcelona Clinic Liver Cancer stage C HCC who were admitted to our center from August 2018 to June 2022 and rec...
A total of 76 patients diagnosed with advanced-stage HCC and treated with ICIs and antiangiogenic therapy were included in the study, with 33 patients in the RT group and 43 patients in the non-RT gro...
In comparison to the combination of ICIs and antiangiogenic therapy, the inclusion of RT has been observed to improve the DCR and survival outcomes in patients with advanced-stage HCC. The safety prof...
Patterned hair loss is a common type of non-scarring alopecia, characterized by miniaturization of hair follicles. The etiology of female pattern hair loss (FPHL) is not clearly linked to androgens or...
